(B) Expansion of molecular genetics and 
immunology studies, including additional animal 
models. 
(C) Global association mapping with single 
nucleotide polymorphisms. 
(D) Identification of environmental trig-
gers and autoantigens in psoriasis. 
(E) Elucidation of specific immune recep-
tor cells and their products involved. 
(F) Pharmcogenetic studies to understand 
the molecular basis for varying patient response 
to treatment. 
(G) Identification of genetic markers of 
psoriatic arthritis susceptibility. 
(H) Research to increase understanding of 
joint inflammation and destruction in psoriatic 
arthritis. 
(I) Clinical research for the development 
and evaluation of new treatments, including 
new biological agents. 
(J) Research to develop improved diag-
nostic tests. 
(K) Research to increase understanding of 
co-morbidities and psoriasis, including shared 
molecular pathways. 
VerDate Aug 31 2005 
03:51 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H1188.IH
H1188
hmoore on PROD1PC68 with HMBILLS
(2) 
COORDINATION
WITH
OTHER
INSTI-
TUTES.—In carrying out paragraph (1), the Director 
of the National Institute of Arthritis and Musculo-
skeletal and Skin Diseases shall coordinate the ac-
tivities of the Institute with the activities of other 
national research institutes and other agencies and 
offices of the National Institutes of Health relating 
to psoriasis or psoriatic arthritis. 
SEC. 5. NATIONAL PATIENT REGISTRY. 
(a) IN GENERAL.—The Secretary, acting through the 
Director of the Centers for Disease Control and Preven-
tion and in collaboration with an eligible national organi-
zation, shall establish a national psoriasis and psoriatic 
arthritis patient registry. 
(b) COOPERATIVE AGREEMENTS.—In carrying out 
subsection (a), the Secretary shall enter into cooperative 
agreements with an eligible national organization and ap-
propriate academic health institutions to develop, imple-
ment, and manage a system for psoriasis and psoriatic ar-
thritis patient data collection and analysis, including the 
creation and use of a common data entry and management 
system. 
(c) LONGITUDINAL DATA.—In carrying out sub-
section (a), the Secretary shall ensure the collection and 
analysis of longitudinal data related to individuals of all 
VerDate Aug 31 2005 
03:51 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H1188.IH
H1188
hmoore on PROD1PC68 with HMBILLS
ages with psoriasis and psoriatic arthritis, including in-
fants, young children, adolescents, and adults of all ages 
including older Americans. 
(d) ELIGIBLE NATIONAL ORGANIZATION.—In this 
section, the term ‘‘eligible national organization’’ means 
a national organization that— 
(1) has expertise in the epidemiology of psori-
asis and psoriatic arthritis; and 
(2) maintains an established patient registry or 
biobank. 
(e) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there are authorized to be appropriated 
$1,000,000 for fiscal year 2008 and $500,000 for each 
of fiscal years 2009 through 2012. 
SEC. 6. NATIONAL SUMMIT. 
(a) IN GENERAL.—Not later than one year after the 
date of enactment of this Act, the Secretary shall convene 
a summit on the current activities of the Federal Govern-
ment to conduct or support research, treatment, edu-
cation, and quality-of-life activities with respect to psori-
asis and psoriatic arthritis, including psoriasis and psori-
atic arthritis related co-morbidities. The summit shall in-
clude researchers, public health professionals, representa-
tives of voluntary health agencies and patient advocacy or-
VerDate Aug 31 2005 
03:51 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H1188.IH
H1188
hmoore on PROD1PC68 with HMBILLS
ganizations, representatives of academic institutions, and 
Federal and State policymakers. 
(b) FOCUS.—The summit convened under this section 
shall focus on— 
(1) a broad range of research activities relating 
to biomedical, epidemiological, psychosocial, and re-
habilitative issues; 
(2) clinical research for the development and 
evaluation of new treatments, including new biologi-
cal agents; 
(3) translational research; 
(4) information and education programs for 
health care professionals and the public; 
(5) priorities among the programs and activities 
of the various Federal agencies involved in psoriasis 
and psoriatic arthritis and psoriasis and psoriatic ar-
thritis related co-morbidities; and 
(6) challenges and opportunities for scientists, 
clinicians, patients, and voluntary organizations. 
(c) REPORT TO CONGRESS.—Not later than 180 days 
after the first day of the summit convened under this sec-
tion, the Secretary shall submit to the Congress and make 
publicly available a report that includes a description of— 
(1) the proceedings at the summit; and 
VerDate Aug 31 2005 
03:51 Feb 22, 2007
Jkt 059200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H1188.IH
H1188
hmoore on PROD1PC68 with HMBILLS